comprehensive -WSS

comprehensive

author：leisure time 2025-09-03 14:40:09 - browse：73

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： My daughter's legacy lives on through her writing, phage therapy

hotspot

WSS

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Readers discuss the intersection of pregnancy and addiction

Study: Why relieving medical debt did not improve financial outcomes

Cigna wins case to block Amy Bricker's move to CVS

Regeneron agrees to White House price limits on anti

Statins may not be needed by millions of people, study suggests

focus

comprehensive

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

What to make of Biden’s latest efforts on cancer research

State Dept. review finds Biden bears some blame for Afghanistan failures

ALS patient reclaims some autonomy thanks to wearable 'robot'

Jerome Adams on the need for new antivirals for Covid

'Essentially witchcraft:' A former naturopath takes on the field

At least 13 dead in Texas as scorching temps continue

Cigna wins case to block Amy Bricker's move to CVS

At least 13 dead in Texas as scorching temps continue

Cheap, fast test for Zika and dengue could cost just $1

hotspot

Curing rare childhood diseases will falter unless Congress steps up

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Acelyrin, a rare IPO success, stumbles in its first big test

Long Covid needs a new name — and a new frame

How to make the FDA’s new prescription one

New report analyzes digital physical therapy solutions' effectiveness

explore

hotspot

explore

entertainment